The Breast Health Center at Lakewood Ranch Medical Center is the first in Manatee and Sarasota Counties to offer the Affirm® Prone Biopsy System 3D™ guided breast biopsy. The Affirm Prone Biopsy System is the world’s first and only dedicated prone biopsy system to offer both 2D and 3D imaging-guided breast biopsies. Many physicians prefer to perform breast biopsies with the patient reclining comfortably in the prone position, removed from the field of view of the biopsy instruments.
The availability of 3D imaging for biopsy guidance facilitates the localization and accurate targeting of lesions, including those that can be challenging to detect with conventional imaging techniques. In addition, this new biopsy technology from Hologic® has several key advantages over standard X-ray biopsy procedures, including faster targeting and fewer X-ray exposures, resulting in shorter patient procedure time and reduced patient dose.
The Breast Health Center is also one of the first in Manatee and Sarasota Counties to offer the SmartCurve™ breast stabilization system, which is clinically proven to deliver a more comfortable mammogram without compromising image quality, workflow or dose1. It also offers the new Clarity HD high-resolution 3D imaging technology, which provides radiologists with the highest resolution 3D images2 to help identify cancers early.
These innovations come as part of Lakewood Ranch Medical Center’s ongoing commitment to superior breast cancer detection and an improved mammogram experience for our patients. The technology increases diagnostic confidence with its exceptional images and has the potential to increase screening volume and compliance for the countless women who have reported avoiding regular mammograms due in large part to the fear of discomfort associated with breast compression.
The SmartCurve system and Clarity HD high-resolution 3D imaging technology are available exclusively with Hologic’s Genius™ 3D Mammography exam, now available at the hospital’s Breast Health Center. The system detects more invasive cancers, reduces false positives, and is FDA approved as superior, compared to conventional 2D mammography for all women, including those with dense breasts.3,4,5
“These new technologies enable us to improve the experience for our patients by providing a more comfortable imaging experience, while also maintaining clinical accuracy with the industry’s fastest, highest resolution 3D images that help to accelerate screening and analysis,” says Shawn Imhoof, Lakewood Ranch Medical Center’s Director of Diagnostic Imaging and Radiology .
“Lakewood Ranch Medical Center is pleased to offer this advanced technology to our community,” said Andy Guz, Chief Executive Officer, Lakewood Ranch Medical Center. “This new technology provides significant advantage to our physicians and their patients. The hospital’s investment in this technology is another affirmation of our commitment to the early detection and diagnosis of this devastating disease.”
The Genius 3D Mammography exam is only available on a Hologic 3D Mammography system. The exam consists of a 2D and 3D image set, where the 2D image can be either an acquired 2D image or a 2D image generated from the 3D image set.
Learn more about the Genius exam
1 Smith, A. Improving Patient Comfort in Mammography. Hologic WP-00119 Rev 003 (2017).
2 Data on file and from public sources, 2017
3 Results from Friedewald, SM, et al. "Breast cancer screening using tomosynthesis in combination with digital mammography." JAMA 311.24 (2014): 2499-2507; a multi-site (13), non-randomized, historical control study of 454,000 screening mammograms investigating the initial impact the introduction of the Hologic Selenia® Dimensions ® on screening outcomes. Individual results may vary. The study found an average 41% (95% CI: 20-65%) increase and that 1.2 (95% CI: 0.8-1.6) additional invasive breast cancers per 1000 screening exams were found in women receiving combined 2D FFDM and 3DÔ mammograms acquired with the Hologic 3D MammographyÔ system versus women receiving 2D FFDM mammograms only.
4 Bernardi D, Macaskill P, Pellegrini M, et. al. Breast cancer screening with tomosynthesis (3D mammography) with acquired or synthetic 2D mammography compared with 2D mammography alone (STORM-2): a population-based prospective study. Lancet Oncol. 2016 Aug;17(8):1105-13.
5 U.S. Food & Drug Administration Premarket Approval (PMA). FDA.gov https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P080003 accessed June 5, 2017.